Zhejiang Anglikang Pharmaceutical Co.,Ltd. (China)

Zhejiang Anglikang Pharmaceutical Co., Ltd. is a modern pharmaceutical company located in Shaoxing, Zhejiang. The company specializes in the production of oral cephalosporins, cardiovascular drugs, and drugs for kidney diseases. It has six subsidiary companies, including Zhejiang Anglikang Capsule Co., Ltd., Zhejiang Anglikang Pharmaceutical Co., Ltd., Jiangsu Yuexin Pharmaceutical Co., Ltd., Zhejiang Angbo Biotechnology Co., Ltd., Zhejiang Kangyun Huapeng Pharmaceutical Co., Ltd., and Zhejiang Anglikang Pharmaceutical Sales Co., Ltd. The company places a strong emphasis on quality and has established a comprehensive quality management system that covers the entire process from product research and development, raw material procurement, production and quality control, warehousing, product distribution, to sales tracking. It has also implemented internal quality standards that exceed national regulations, ensuring product quality. Zhejiang Anglikang Pharmaceutical Co., Ltd. is committed to research and development innovation. As a national high-tech enterprise, it leverages excellent research and development platforms such as key enterprise research institutes, provincial enterprise technology centers, academician expert workstations, foreign expert workstations, and postdoctoral workstations. The company has accumulated a wealth of core technologies and has an outstanding research and development team, laying a solid foundation for independent drug research and development. It has successfully transitioned from generic drugs to innovative drugs. The company values collaboration within the industry and strives to create greater value for its upstream and downstream partners. It engages in cooperative production with companies such as Meifuren, Ningbo Sanyuan, and Zhuhai Youbang, and collaborates on research and development with companies like Wanpeng Langge, Suzhou Jingyun, and Hongbo Zhiyuan. It also collaborates with a team of returnee researchers to explore the field of innovative drugs and has established joint ventures with industry leaders such as the German company Fresenius Kabi and the domestic pharmaceutical company Guangzhou Baiyunshan. The company aims to shift from competition to cooperation and share cutting-edge technology and market trends with domestic and international peers. Zhejiang Anglikang Pharmaceutical Co., Ltd. prioritizes social responsibility and actively participates in caring for vulnerable groups. It has jointly established the "Zhejiang Anglikang Leukemia Assistance Fund" with the Shengzhou Red Cross, providing assistance to families in need. The company also actively participates in targeted poverty alleviation and has partnered with Miao Jiacun in Luoyou County. It strives for excellence in corporate governance, safety management, green development, and social affairs, aiming to achieve harmony and win-win situations and embodying the responsibility and compassion of Anglikang employees. Looking to the future, the company will continue to focus on the pharmaceutical industry, integrate internal and external resources, and seize the opportunity to go public. It will increase investment in technological transformation and research and development innovation, adhering to the values of "integrity, passion, professionalism, respect, and cooperation." With the vision of "healthy development, industry top 100," the company aims to become a competitive and innovative international pharmaceutical enterprise within the industry.